Aurora Spine Corporation (ASAPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aurora Spine Corporation (ASAPF) trades at $0.17 with AI Score 48/100 (Grade C). Aurora Spine Corporation develops and distributes minimally invasive interspinous fusion systems and devices. Market cap: $13.32M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ASAPF: ASAPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ASAPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ASAPF: the 1 perspectives are evenly split.
How is this calculated? →Aurora Spine Corporation (ASAPF) Healthcare & Pipeline Overview
Aurora Spine Corporation, a Canadian medical device company, specializes in minimally invasive spinal fusion technologies, including interspinous fusion devices and interbody cages, targeting patients with degenerative disc diseases. With a focus on innovation and 3D-printed implants, Aurora Spine operates within the competitive medical device landscape.
What Is the Investment Thesis for ASAPF?
Aurora Spine Corporation presents a focused investment opportunity within the medical device sector, specifically targeting the spinal fusion market. The company's emphasis on minimally invasive techniques and innovative products like the SOLO and DEXA-C devices could drive future growth. With a market capitalization of $13.32M, Aurora Spine operates with a negative P/E ratio of -11.66 and a negative profit margin of -7.4%, indicating potential for improved profitability. A gross margin of 59.7% suggests efficient production and pricing strategies. Key catalysts include expanding distribution networks and securing regulatory approvals for new products. However, investors should be aware of the risks associated with the OTC market and the company's current financial performance.
Based on FMP financials and quantitative analysis
ASAPF Key Highlights
- Market capitalization of $13.32M indicates a small-cap company with potential for growth.
- Negative P/E ratio of -11.66 reflects current unprofitability, suggesting potential for future earnings improvement.
- Gross margin of 59.7% demonstrates efficient cost management in product manufacturing and sales.
- Beta of -0.54 suggests the stock is less volatile than the market, potentially offering stability during market downturns.
- Focus on minimally invasive spinal fusion technologies positions the company in a growing segment of the medical device market.
Who Are ASAPF's Competitors?
ASAPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.87 | -5.97% | $39.39M | 45 |
| EMITF Elbit Imaging Ltd. | $1.60 | +0.00% | $21.25M | 42 |
| GTHP Guided Therapeutics, Inc. | $0.28 | +14.29% | $21.48M | 44 |
| IMMVF Immunovia AB (publ) | $0.02 | +0.00% | $6.11M | 39 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ASAPF's Key Strengths?
- Innovative interspinous fusion technology.
- Focus on minimally invasive solutions.
- 3D-printing capabilities for customized implants.
- Established distribution network in Canada.
What Are ASAPF's Weaknesses?
- Limited market presence outside of Canada.
- Negative profitability and reliance on external funding.
- Small market capitalization and limited resources.
- Dependence on key product lines.
What Could Drive ASAPF Stock Higher?
- FDA approval for key products (ZIP, SOLO) for US market entry.
- Strategic partnerships with hospitals and surgical centers to expand distribution.
- Increasing adoption of 3D-printed implants in spinal fusion procedures.
- Development and launch of new spinal fusion technologies.
- Expansion of sales and marketing efforts in the Canadian market.
What Are the Key Risks for ASAPF?
- Financial-distress signal — its Altman Z-Score of -0.35 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-15.6%) — the business is not currently generating profit on shareholder capital.
- Competition from larger medical device companies with greater resources.
- Regulatory hurdles and delays in obtaining FDA approvals.
- Product liability and litigation risks associated with spinal implants.
- Negative profitability and reliance on external funding.
- Limited market presence outside of Canada.
What Are the Growth Opportunities for ASAPF?
- Expansion into the US Market: Aurora Spine has the opportunity to expand its market reach into the United States, a significantly larger market for spinal implants. Securing FDA approval for its key products, such as the ZIP and SOLO systems, would be crucial for this expansion. The US spinal implant market is estimated to be worth billions of dollars annually, offering substantial revenue potential for Aurora Spine. Timeline: 2-3 years for regulatory approvals and market entry.
- Increased Adoption of 3D-Printed Implants: Aurora Spine's DEXA-C cervical interbody system, which utilizes 3D-printed technology, presents a growth opportunity. As 3D printing becomes more prevalent in medical device manufacturing, Aurora Spine can capitalize on the demand for customized and porous implants that promote bone growth. The 3D-printed medical device market is experiencing rapid growth, driven by its ability to create patient-specific solutions. Timeline: Ongoing, with increasing adoption over the next 5 years.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with hospitals, surgical centers, and distributors can accelerate Aurora Spine's market penetration. Collaborations with established players in the medical device industry can provide access to wider distribution networks and increased brand visibility. These partnerships can also facilitate the adoption of Aurora Spine's products by surgeons and healthcare providers. Timeline: 1-2 years to establish key partnerships.
- Development of New Spinal Fusion Technologies: Investing in research and development to create new and innovative spinal fusion technologies can drive future growth. Focusing on areas such as motion preservation, regenerative medicine, and personalized implants can differentiate Aurora Spine from its competitors. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry. Timeline: Ongoing, with new product launches every 2-3 years.
- Focus on Minimally Invasive Surgical Techniques: The increasing demand for minimally invasive surgical procedures presents a growth opportunity for Aurora Spine. The company's ZIP system and other interspinous fusion devices align with this trend, offering patients less invasive alternatives to traditional spinal fusion. As more surgeons adopt minimally invasive techniques, the demand for Aurora Spine's products is expected to increase. Timeline: Ongoing, with increasing adoption over the next 5 years.
What Opportunities Does ASAPF Have?
- Expansion into the US market.
- Increased adoption of 3D-printed implants.
- Strategic partnerships and distribution agreements.
- Development of new spinal fusion technologies.
What Threats Does ASAPF Face?
- Competition from larger medical device companies.
- Regulatory hurdles and approval processes.
- Product liability and litigation risks.
- Economic downturns and healthcare spending cuts.
What Are ASAPF's Competitive Advantages?
- Proprietary interspinous fusion technology (ZIP system).
- Focus on minimally invasive surgical techniques.
- 3D-printed implant capabilities (DEXA-C).
- Established presence in the Canadian market.
What Does ASAPF Do?
Aurora Spine Corporation, established in 2013 and headquartered in Toronto, Canada, operates through its subsidiary, Aurora Spine, Inc., focusing on the design, development, and commercialization of minimally invasive spinal implant systems. The company's core business revolves around addressing spinal pathologies through innovative interspinous fusion and interbody technologies. Their product portfolio includes a range of interspinous process lumbar fusion devices like the ZIP family (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51), designed to alleviate pain and stabilize the spine in patients with degenerative disc diseases. These devices offer a less invasive alternative to traditional spinal fusion surgeries. In addition to interspinous devices, Aurora Spine offers Ti-Coated polyether ether ketone (PEEK) interbody cages, which provide structural support and promote bone growth between vertebrae during fusion. The company also provides sterile-packed titanium plasma spray coated spinal infusion implants. Their interbody product line includes EOS, VOX, Echo, Echo SD, and EchoXL for lumbar applications, and Discovery for cervical procedures. Aurora Spine has also introduced SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, and SiLo, a posterior fusion device for the sacroiliac joint. Further expanding their offerings, DEXA-C, a cervical interbody system, utilizes porous 3D-printed intervertebral body fusion devices with customizable lattice patterns to match individual patient bone quality. Aurora Spine primarily serves the Canadian market, focusing on providing advanced spinal solutions to improve patient outcomes and quality of life.
What Products and Services Does ASAPF Offer?
- Develops minimally invasive interspinous fusion systems.
- Distributes spinal implants and devices.
- Offers interspinous process lumbar fusion devices (ZIP, ZIP ULTRA, ZIP LP, ZIP-51).
- Provides Ti-Coated polyether ether ketone interbody cages.
- Manufactures sterile-packed titanium plasma spray coated spinal infusion implants.
- Offers interbody products (EOS, VOX, Echo, Echo SD, EchoXL, Discovery).
- Provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device.
- Offers SiLo, a posterior fusion device for the sacroiliac joint.
How Does ASAPF Make Money?
- Develops and manufactures spinal implants and devices.
- Sells products directly to hospitals and surgical centers.
- Utilizes distributors to reach a wider customer base.
- Generates revenue through the sale of its spinal fusion products.
What Industry Does ASAPF Operate In?
Aurora Spine Corporation operates within the medical device industry, specifically focusing on spinal implants and fusion technologies. The global spinal implants and surgery devices market is projected to reach billions of dollars by 2026, driven by an aging population, increasing prevalence of spinal disorders, and advancements in minimally invasive surgical techniques. The competitive landscape includes established players like BTCY, CLCS, EMITF, GTHP, and IMMVF, as well as larger medical device companies. Aurora Spine differentiates itself through its focus on innovative designs, 3D-printed implants, and interspinous fusion devices.
Who Are ASAPF's Key Customers?
- Hospitals
- Surgical centers
- Spinal surgeons
- Patients suffering from degenerative disc diseases
Aurora Spine Corporation Financial Trajectory
Aurora Spine Corporation (ASAPF) reported $4.4M in revenue for Q1 2026, a decline of 14.2% compared to the prior quarter. The company recorded a net loss of $200K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ASAPF averaged $-0.00 in diluted EPS.
Company Profile
Aurora Spine Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Trent J. Northcutt. ASAPF has traded publicly since 2013.
How Aurora Spine Corporation Is Valued
Aurora Spine Corporation carries a market capitalization of $13.32M, placing it in the micro-cap category. Relative to its peer group, ASAPF's quantitative score of 48/100 is roughly in line with the peer average of 49/100.
ROE -16%Key Financial Metrics
Return on equity for Aurora Spine Corporation stands at -15.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Aurora Spine Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.35 places it in the distress zone, a signal of elevated financial risk.
ASAPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Aurora Spine's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative spinal implant technologies gaining traction.
- Recent partnerships and collaborations have bolstered market perception, showcasing Aurora's commitment to advancing spinal health solutions.
- The growing demand for minimally invasive surgical options aligns well with Aurora's product offerings, positioning the company favorably in a competitive landscape.
Bear Case
- Concerns over regulatory hurdles in the medical device industry could impact Aurora's growth trajectory, creating uncertainty among investors.
- Recent social sentiment reflects skepticism regarding the company's ability to scale operations effectively amidst increasing competition.
- Some community members express doubts about the sustainability of Aurora's recent product launches, fearing they may not meet market expectations.
- Ongoing supply chain challenges in the healthcare sector could hinder Aurora's production capabilities, leading to potential delays in product availability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4M | -$200,044 | -$0.0026 |
| Q4 2025 | $5M | -$41,327 | -$0.0006 |
| Q3 2025 | $4M | -$140,405 | -$0.0018 |
| Q2 2025 | $4M | -$198,760 | -$0.0026 |
Based on FMP financials and quantitative analysis
ASAPF Latest News
-
Aurora Spine Grants Stock Options
feeds.newsfilecorp.com · Jun 9, 2026
-
Aurora Spine Corp (ASAPF) Q1 2026 Earnings Call Highlights: Strategic Expansions and Product ...
Yahoo! Finance: ASAPF News · May 28, 2026
-
Aurora Spine Corporation (ASG:CA) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 28, 2026
-
Aurora Spine Corporation Announces First Quarter FY26 Financial Results
globenewswire.com · May 28, 2026
ASAPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASAPF.
Price Targets
Wall Street price target analysis for ASAPF.
ASAPF MoonshotScore
What does this score mean?
The MoonshotScore rates ASAPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Aurora Spine Grants Stock Options
Aurora Spine Corp (ASAPF) Q1 2026 Earnings Call Highlights: Strategic Expansions and Product ...
Aurora Spine Corporation (ASG:CA) Q1 2026 Earnings Call Transcript
Aurora Spine Corporation Announces First Quarter FY26 Financial Results
Leadership: Trent J. Northcutt
Unknown
Information on Trent J. Northcutt's background is not available in the provided context. Further research would be needed to provide details on his career history, education, and previous roles.
Track Record: Information on Trent J. Northcutt's track record is not available in the provided context. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under his leadership.
ASAPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aurora Spine Corporation may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of price manipulation.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Company has been in operation since 2013.
- Focus on developing and distributing medical devices.
- Presence of a physical headquarters in Toronto, Canada.
- Product portfolio includes multiple spinal fusion devices.
What Investors Ask About Aurora Spine Corporation (ASAPF) — Healthcare
What does Aurora Spine Corporation do?
Aurora Spine Corporation is a medical device company specializing in the design, development, and commercialization of minimally invasive spinal implant systems. The company's primary focus is on providing solutions for patients suffering from degenerative disc diseases and other spinal conditions. Their product portfolio includes interspinous fusion devices, interbody cages, and 3D-printed implants, all designed to improve patient outcomes and quality of life. Aurora Spine primarily serves the Canadian market, offering advanced spinal solutions to hospitals, surgical centers, and spinal surgeons.
What do analysts say about ASAPF stock?
As of 2026-03-16, formal analyst ratings for Aurora Spine Corporation (ASAPF) are limited due to its OTC listing and small market capitalization. Key valuation metrics include a negative P/E ratio, reflecting current unprofitability, and a gross margin of 59.7%, indicating efficient cost management. Growth considerations center on the company's ability to expand into the US market, secure regulatory approvals, and increase adoption of its innovative spinal fusion technologies. Investors should conduct their own due diligence and consider the risks associated with OTC-listed stocks.
What are the main risks for ASAPF?
Aurora Spine Corporation faces several risks, including competition from larger medical device companies, regulatory hurdles in obtaining FDA approvals for US market expansion, and potential product liability claims associated with spinal implants. The company's negative profitability and reliance on external funding also pose financial risks. Additionally, its limited market presence outside of Canada and dependence on key product lines could impact future growth. Investors should carefully consider these risks before investing in ASAPF.
What are the key factors to evaluate for ASAPF?
Aurora Spine Corporation (ASAPF) holds an AI score of 48/100 (low). Not financial advice.
How frequently does ASAPF data refresh on this page?
ASAPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ASAPF's recent stock price performance?
Aurora Spine Corporation (ASAPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative interspinous fusion technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ASAPF overvalued or undervalued right now?
Valuing Aurora Spine Corporation (ASAPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ASAPF?
Before investing in Aurora Spine Corporation (ASAPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market stocks carry higher risk than exchange-listed stocks.